Impact of COVID-19 on HV trials [Study Per­for­mance]

posted by jag009  – NJ, 2020-04-21 23:04 (1021 d 17:44 ago) – Posting: # 21341
Views: 1,989

Hi,

No. Too many uncertainties since I dont think we have a clear understanding of the route(s) of transmission yet. Also you are risking the safety of the staff (those who go to HV's home, as an example).

J

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
16 visitors (0 registered, 16 guests [including 7 identified bots]).
Forum time: 15:48 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5